RecruitingPhase 1NCT05806814

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)

Sponsor

University of Oklahoma

Enrollment

13 participants

Start Date

Nov 12, 2023

Study Type

INTERVENTIONAL

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Summary

Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating Sipuleucel-T (also known as Provenge), an immune-based therapy that uses your own immune cells to fight advanced prostate cancer that no longer responds to hormone therapy. **You may be eligible if...** - You are a man aged 18 or older with prostate cancer that has spread (metastatic) - Your cancer has stopped responding to hormone therapy (castrate-resistant) - You have mild or no symptoms from the cancer - You are in generally good physical health - You have a life expectancy of at least 6 months **You may NOT be eligible if...** - You have previously received Sipuleucel-T (Provenge) - You have another active cancer requiring treatment - You are in poor overall health Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALSipuleucel-T

Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.

Locations(1)

University of Oklahoma Health Sciences Center, Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05806814

Related Trials

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT0346097783 locations

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

NCT074935123 locations

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650329 locations

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

NCT072856949 locations

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

NCT076216922 locations